nodes	percent_of_prediction	percent_of_DWPC	metapath
Modafinil—CYP3A5—Beclomethasone—psoriasis	0.0849	0.124	CbGbCtD
Modafinil—CYP1A2—Clobetasol propionate—psoriasis	0.0834	0.122	CbGbCtD
Modafinil—CYP2B6—Cholecalciferol—psoriasis	0.0495	0.0725	CbGbCtD
Modafinil—CYP1A2—Methoxsalen—psoriasis	0.0438	0.0642	CbGbCtD
Modafinil—CYP3A5—Mycophenolate mofetil—psoriasis	0.0338	0.0495	CbGbCtD
Modafinil—CYP2C19—Cholecalciferol—psoriasis	0.0315	0.0461	CbGbCtD
Modafinil—CYP3A4—Calcitriol—psoriasis	0.0295	0.0432	CbGbCtD
Modafinil—CYP3A5—Hydrocortisone—psoriasis	0.0271	0.0397	CbGbCtD
Modafinil—CYP2C9—Cholecalciferol—psoriasis	0.0261	0.0383	CbGbCtD
Modafinil—CYP3A5—Cyclosporine—psoriasis	0.0256	0.0375	CbGbCtD
Modafinil—CYP3A4—Methoxsalen—psoriasis	0.023	0.0336	CbGbCtD
Modafinil—CYP2C19—Prednisone—psoriasis	0.0218	0.0319	CbGbCtD
Modafinil—CYP2B6—Dexamethasone—psoriasis	0.0214	0.0314	CbGbCtD
Modafinil—CYP2C19—Cyclosporine—psoriasis	0.0207	0.0303	CbGbCtD
Modafinil—CYP2C9—Cyclosporine—psoriasis	0.0172	0.0252	CbGbCtD
Modafinil—CYP3A5—Dexamethasone—psoriasis	0.0169	0.0247	CbGbCtD
Modafinil—CYP3A4—Cholecalciferol—psoriasis	0.0152	0.0223	CbGbCtD
Modafinil—CYP2C19—Dexamethasone—psoriasis	0.0136	0.0199	CbGbCtD
Modafinil—CYP3A4—Triamcinolone—psoriasis	0.0132	0.0193	CbGbCtD
Modafinil—CYP3A4—Mycophenolate mofetil—psoriasis	0.0132	0.0193	CbGbCtD
Modafinil—CYP2C9—Dexamethasone—psoriasis	0.0113	0.0166	CbGbCtD
Modafinil—CYP3A4—Betamethasone—psoriasis	0.0113	0.0166	CbGbCtD
Modafinil—CYP3A4—Prednisolone—psoriasis	0.0112	0.0163	CbGbCtD
Modafinil—CYP3A4—Hydrocortisone—psoriasis	0.0106	0.0155	CbGbCtD
Modafinil—CYP3A4—Prednisone—psoriasis	0.0105	0.0154	CbGbCtD
Modafinil—CYP3A4—Cyclosporine—psoriasis	0.00999	0.0146	CbGbCtD
Modafinil—CYP3A4—Dexamethasone—psoriasis	0.00658	0.00964	CbGbCtD
Modafinil—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00125	0.0793	CbGpPWpGaD
Modafinil—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000944	0.0599	CbGpPWpGaD
Modafinil—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000861	0.0547	CbGpPWpGaD
Modafinil—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.000774	0.0492	CbGpPWpGaD
Modafinil—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000757	0.0481	CbGpPWpGaD
Modafinil—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000585	0.0372	CbGpPWpGaD
Modafinil—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000534	0.0339	CbGpPWpGaD
Modafinil—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000456	0.029	CbGpPWpGaD
Modafinil—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000352	0.0223	CbGpPWpGaD
Modafinil—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000322	0.0204	CbGpPWpGaD
Modafinil—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000317	0.0202	CbGpPWpGaD
Modafinil—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000314	0.02	CbGpPWpGaD
Modafinil—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00031	0.0197	CbGpPWpGaD
Modafinil—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000261	0.0166	CbGpPWpGaD
Modafinil—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000255	0.0162	CbGpPWpGaD
Modafinil—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000243	0.0154	CbGpPWpGaD
Modafinil—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00024	0.0152	CbGpPWpGaD
Modafinil—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000222	0.0141	CbGpPWpGaD
Modafinil—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000219	0.0139	CbGpPWpGaD
Modafinil—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000197	0.0125	CbGpPWpGaD
Modafinil—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000189	0.012	CbGpPWpGaD
Modafinil—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000187	0.0119	CbGpPWpGaD
Modafinil—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00018	0.0114	CbGpPWpGaD
Modafinil—ADRA1B—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000168	0.0107	CbGpPWpGaD
Modafinil—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000166	0.0106	CbGpPWpGaD
Modafinil—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000153	0.00975	CbGpPWpGaD
Modafinil—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000148	0.00938	CbGpPWpGaD
Modafinil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000146	0.00928	CbGpPWpGaD
Modafinil—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000144	0.00916	CbGpPWpGaD
Modafinil—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000138	0.00879	CbGpPWpGaD
Modafinil—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000137	0.00867	CbGpPWpGaD
Modafinil—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000135	0.00859	CbGpPWpGaD
Modafinil—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000133	0.00848	CbGpPWpGaD
Modafinil—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000123	0.00778	CbGpPWpGaD
Modafinil—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000118	0.00752	CbGpPWpGaD
Modafinil—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000117	0.00742	CbGpPWpGaD
Modafinil—SLC6A3—NRF2 pathway—TGFA—psoriasis	0.000114	0.00726	CbGpPWpGaD
Modafinil—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000105	0.00664	CbGpPWpGaD
Modafinil—SLC6A3—Dopaminergic Neurogenesis—STAT3—psoriasis	0.000104	0.00658	CbGpPWpGaD
Modafinil—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000103	0.00655	CbGpPWpGaD
Modafinil—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000103	0.00654	CbGpPWpGaD
Modafinil—Myalgia—Dexamethasone—psoriasis	0.000103	0.000341	CcSEcCtD
Modafinil—Myalgia—Betamethasone—psoriasis	0.000103	0.000341	CcSEcCtD
Modafinil—Body temperature increased—Cyclosporine—psoriasis	0.000103	0.00034	CcSEcCtD
Modafinil—Abdominal pain—Cyclosporine—psoriasis	0.000103	0.00034	CcSEcCtD
Modafinil—Anxiety—Betamethasone—psoriasis	0.000102	0.00034	CcSEcCtD
Modafinil—Anxiety—Dexamethasone—psoriasis	0.000102	0.00034	CcSEcCtD
Modafinil—Vomiting—Mycophenolic acid—psoriasis	0.000102	0.000338	CcSEcCtD
Modafinil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000102	0.00646	CbGpPWpGaD
Modafinil—Discomfort—Betamethasone—psoriasis	0.000102	0.000337	CcSEcCtD
Modafinil—Discomfort—Dexamethasone—psoriasis	0.000102	0.000337	CcSEcCtD
Modafinil—Dyspepsia—Hydrocortisone—psoriasis	0.000102	0.000337	CcSEcCtD
Modafinil—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000101	0.00644	CbGpPWpGaD
Modafinil—Rash—Mycophenolic acid—psoriasis	0.000101	0.000336	CcSEcCtD
Modafinil—Dermatitis—Mycophenolic acid—psoriasis	0.000101	0.000335	CcSEcCtD
Modafinil—Pain—Prednisolone—psoriasis	0.000101	0.000335	CcSEcCtD
Modafinil—Urticaria—Mycophenolate mofetil—psoriasis	0.000101	0.000334	CcSEcCtD
Modafinil—Headache—Mycophenolic acid—psoriasis	0.000101	0.000333	CcSEcCtD
Modafinil—Decreased appetite—Hydrocortisone—psoriasis	0.0001	0.000333	CcSEcCtD
Modafinil—Pharyngitis—Methotrexate—psoriasis	0.0001	0.000332	CcSEcCtD
Modafinil—Body temperature increased—Mycophenolate mofetil—psoriasis	0.0001	0.000332	CcSEcCtD
Modafinil—Abdominal pain—Mycophenolate mofetil—psoriasis	0.0001	0.000332	CcSEcCtD
Modafinil—Urinary tract disorder—Methotrexate—psoriasis	9.97e-05	0.000331	CcSEcCtD
Modafinil—Gastrointestinal disorder—Hydrocortisone—psoriasis	9.96e-05	0.00033	CcSEcCtD
Modafinil—Fatigue—Hydrocortisone—psoriasis	9.95e-05	0.00033	CcSEcCtD
Modafinil—Urethral disorder—Methotrexate—psoriasis	9.9e-05	0.000328	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Triamcinolone—psoriasis	9.9e-05	0.000328	CcSEcCtD
Modafinil—Pain—Hydrocortisone—psoriasis	9.86e-05	0.000327	CcSEcCtD
Modafinil—Oedema—Dexamethasone—psoriasis	9.86e-05	0.000327	CcSEcCtD
Modafinil—Anaphylactic shock—Dexamethasone—psoriasis	9.86e-05	0.000327	CcSEcCtD
Modafinil—Anaphylactic shock—Betamethasone—psoriasis	9.86e-05	0.000327	CcSEcCtD
Modafinil—Oedema—Betamethasone—psoriasis	9.86e-05	0.000327	CcSEcCtD
Modafinil—Insomnia—Triamcinolone—psoriasis	9.82e-05	0.000326	CcSEcCtD
Modafinil—Infection—Dexamethasone—psoriasis	9.79e-05	0.000325	CcSEcCtD
Modafinil—Infection—Betamethasone—psoriasis	9.79e-05	0.000325	CcSEcCtD
Modafinil—Ill-defined disorder—Prednisone—psoriasis	9.76e-05	0.000324	CcSEcCtD
Modafinil—Paraesthesia—Triamcinolone—psoriasis	9.75e-05	0.000324	CcSEcCtD
Modafinil—Feeling abnormal—Prednisolone—psoriasis	9.73e-05	0.000323	CcSEcCtD
Modafinil—Visual impairment—Methotrexate—psoriasis	9.73e-05	0.000323	CcSEcCtD
Modafinil—Anaemia—Prednisone—psoriasis	9.72e-05	0.000322	CcSEcCtD
Modafinil—Shock—Dexamethasone—psoriasis	9.7e-05	0.000322	CcSEcCtD
Modafinil—Shock—Betamethasone—psoriasis	9.7e-05	0.000322	CcSEcCtD
Modafinil—Dyspnoea—Triamcinolone—psoriasis	9.68e-05	0.000321	CcSEcCtD
Modafinil—Nervous system disorder—Betamethasone—psoriasis	9.67e-05	0.000321	CcSEcCtD
Modafinil—Nervous system disorder—Dexamethasone—psoriasis	9.67e-05	0.000321	CcSEcCtD
Modafinil—Agitation—Prednisone—psoriasis	9.66e-05	0.000321	CcSEcCtD
Modafinil—Tachycardia—Betamethasone—psoriasis	9.62e-05	0.000319	CcSEcCtD
Modafinil—Tachycardia—Dexamethasone—psoriasis	9.62e-05	0.000319	CcSEcCtD
Modafinil—Angioedema—Prednisone—psoriasis	9.61e-05	0.000319	CcSEcCtD
Modafinil—Hypersensitivity—Cyclosporine—psoriasis	9.56e-05	0.000317	CcSEcCtD
Modafinil—Dyspepsia—Triamcinolone—psoriasis	9.56e-05	0.000317	CcSEcCtD
Modafinil—Erythema multiforme—Methotrexate—psoriasis	9.55e-05	0.000317	CcSEcCtD
Modafinil—CYP2C9—Biological oxidations—CYP2S1—psoriasis	9.54e-05	0.00606	CbGpPWpGaD
Modafinil—Nausea—Mycophenolic acid—psoriasis	9.53e-05	0.000316	CcSEcCtD
Modafinil—Hyperhidrosis—Dexamethasone—psoriasis	9.53e-05	0.000316	CcSEcCtD
Modafinil—Hyperhidrosis—Betamethasone—psoriasis	9.53e-05	0.000316	CcSEcCtD
Modafinil—Feeling abnormal—Hydrocortisone—psoriasis	9.51e-05	0.000315	CcSEcCtD
Modafinil—Malaise—Prednisone—psoriasis	9.48e-05	0.000315	CcSEcCtD
Modafinil—Vertigo—Prednisone—psoriasis	9.45e-05	0.000313	CcSEcCtD
Modafinil—Gastrointestinal pain—Hydrocortisone—psoriasis	9.43e-05	0.000313	CcSEcCtD
Modafinil—Syncope—Prednisone—psoriasis	9.43e-05	0.000313	CcSEcCtD
Modafinil—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	9.41e-05	0.00598	CbGpPWpGaD
Modafinil—Anorexia—Betamethasone—psoriasis	9.39e-05	0.000312	CcSEcCtD
Modafinil—Anorexia—Dexamethasone—psoriasis	9.39e-05	0.000312	CcSEcCtD
Modafinil—Urticaria—Prednisolone—psoriasis	9.38e-05	0.000311	CcSEcCtD
Modafinil—Cardiac disorder—Methotrexate—psoriasis	9.37e-05	0.000311	CcSEcCtD
Modafinil—Fatigue—Triamcinolone—psoriasis	9.37e-05	0.000311	CcSEcCtD
Modafinil—ADRA1B—GPCR ligand binding—HCAR2—psoriasis	9.33e-05	0.00593	CbGpPWpGaD
Modafinil—Hypersensitivity—Mycophenolate mofetil—psoriasis	9.33e-05	0.000309	CcSEcCtD
Modafinil—Asthenia—Cyclosporine—psoriasis	9.31e-05	0.000309	CcSEcCtD
Modafinil—Pain—Triamcinolone—psoriasis	9.29e-05	0.000308	CcSEcCtD
Modafinil—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	9.28e-05	0.00589	CbGpPWpGaD
Modafinil—Loss of consciousness—Prednisone—psoriasis	9.24e-05	0.000307	CcSEcCtD
Modafinil—Hypotension—Betamethasone—psoriasis	9.21e-05	0.000306	CcSEcCtD
Modafinil—Hypotension—Dexamethasone—psoriasis	9.21e-05	0.000306	CcSEcCtD
Modafinil—Pruritus—Cyclosporine—psoriasis	9.18e-05	0.000305	CcSEcCtD
Modafinil—Urticaria—Hydrocortisone—psoriasis	9.16e-05	0.000304	CcSEcCtD
Modafinil—Angiopathy—Methotrexate—psoriasis	9.16e-05	0.000304	CcSEcCtD
Modafinil—Immune system disorder—Methotrexate—psoriasis	9.12e-05	0.000303	CcSEcCtD
Modafinil—Body temperature increased—Hydrocortisone—psoriasis	9.12e-05	0.000303	CcSEcCtD
Modafinil—Abdominal pain—Hydrocortisone—psoriasis	9.12e-05	0.000303	CcSEcCtD
Modafinil—Convulsion—Prednisone—psoriasis	9.11e-05	0.000302	CcSEcCtD
Modafinil—Mediastinal disorder—Methotrexate—psoriasis	9.1e-05	0.000302	CcSEcCtD
Modafinil—Asthenia—Mycophenolate mofetil—psoriasis	9.09e-05	0.000301	CcSEcCtD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	9.08e-05	0.00577	CbGpPWpGaD
Modafinil—Hypertension—Prednisone—psoriasis	9.08e-05	0.000301	CcSEcCtD
Modafinil—Chills—Methotrexate—psoriasis	9.06e-05	0.000301	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Dexamethasone—psoriasis	8.98e-05	0.000298	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Betamethasone—psoriasis	8.98e-05	0.000298	CcSEcCtD
Modafinil—Pruritus—Mycophenolate mofetil—psoriasis	8.96e-05	0.000297	CcSEcCtD
Modafinil—Myalgia—Prednisone—psoriasis	8.95e-05	0.000297	CcSEcCtD
Modafinil—Arthralgia—Prednisone—psoriasis	8.95e-05	0.000297	CcSEcCtD
Modafinil—Feeling abnormal—Triamcinolone—psoriasis	8.95e-05	0.000297	CcSEcCtD
Modafinil—Anxiety—Prednisone—psoriasis	8.92e-05	0.000296	CcSEcCtD
Modafinil—Insomnia—Dexamethasone—psoriasis	8.91e-05	0.000296	CcSEcCtD
Modafinil—Insomnia—Betamethasone—psoriasis	8.91e-05	0.000296	CcSEcCtD
Modafinil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	8.89e-05	0.000295	CcSEcCtD
Modafinil—Diarrhoea—Cyclosporine—psoriasis	8.88e-05	0.000295	CcSEcCtD
Modafinil—Paraesthesia—Betamethasone—psoriasis	8.85e-05	0.000294	CcSEcCtD
Modafinil—Paraesthesia—Dexamethasone—psoriasis	8.85e-05	0.000294	CcSEcCtD
Modafinil—Discomfort—Prednisone—psoriasis	8.85e-05	0.000293	CcSEcCtD
Modafinil—Mental disorder—Methotrexate—psoriasis	8.85e-05	0.000293	CcSEcCtD
Modafinil—Malnutrition—Methotrexate—psoriasis	8.79e-05	0.000292	CcSEcCtD
Modafinil—Hypersensitivity—Prednisolone—psoriasis	8.7e-05	0.000289	CcSEcCtD
Modafinil—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.7e-05	0.00552	CbGpPWpGaD
Modafinil—Dyspepsia—Dexamethasone—psoriasis	8.68e-05	0.000288	CcSEcCtD
Modafinil—Dyspepsia—Betamethasone—psoriasis	8.68e-05	0.000288	CcSEcCtD
Modafinil—ADRA1B—AMPK Signaling—LEP—psoriasis	8.67e-05	0.00551	CbGpPWpGaD
Modafinil—Diarrhoea—Mycophenolate mofetil—psoriasis	8.66e-05	0.000287	CcSEcCtD
Modafinil—Urticaria—Triamcinolone—psoriasis	8.63e-05	0.000286	CcSEcCtD
Modafinil—Dysgeusia—Methotrexate—psoriasis	8.61e-05	0.000286	CcSEcCtD
Modafinil—Body temperature increased—Triamcinolone—psoriasis	8.59e-05	0.000285	CcSEcCtD
Modafinil—Dizziness—Cyclosporine—psoriasis	8.58e-05	0.000285	CcSEcCtD
Modafinil—Oedema—Prednisone—psoriasis	8.58e-05	0.000285	CcSEcCtD
Modafinil—Anaphylactic shock—Prednisone—psoriasis	8.58e-05	0.000285	CcSEcCtD
Modafinil—ADRA1B—LPA receptor mediated events—NFKBIA—psoriasis	8.58e-05	0.00545	CbGpPWpGaD
Modafinil—Decreased appetite—Betamethasone—psoriasis	8.57e-05	0.000284	CcSEcCtD
Modafinil—Decreased appetite—Dexamethasone—psoriasis	8.57e-05	0.000284	CcSEcCtD
Modafinil—Infection—Prednisone—psoriasis	8.53e-05	0.000283	CcSEcCtD
Modafinil—SLC6A3—Monoamine Transport—TNF—psoriasis	8.52e-05	0.00541	CbGpPWpGaD
Modafinil—Gastrointestinal disorder—Dexamethasone—psoriasis	8.51e-05	0.000282	CcSEcCtD
Modafinil—Gastrointestinal disorder—Betamethasone—psoriasis	8.51e-05	0.000282	CcSEcCtD
Modafinil—Back pain—Methotrexate—psoriasis	8.5e-05	0.000282	CcSEcCtD
Modafinil—Hypersensitivity—Hydrocortisone—psoriasis	8.5e-05	0.000282	CcSEcCtD
Modafinil—Fatigue—Betamethasone—psoriasis	8.5e-05	0.000282	CcSEcCtD
Modafinil—Fatigue—Dexamethasone—psoriasis	8.5e-05	0.000282	CcSEcCtD
Modafinil—Shock—Prednisone—psoriasis	8.44e-05	0.00028	CcSEcCtD
Modafinil—Pain—Betamethasone—psoriasis	8.43e-05	0.00028	CcSEcCtD
Modafinil—Pain—Dexamethasone—psoriasis	8.43e-05	0.00028	CcSEcCtD
Modafinil—Nervous system disorder—Prednisone—psoriasis	8.42e-05	0.000279	CcSEcCtD
Modafinil—Tachycardia—Prednisone—psoriasis	8.38e-05	0.000278	CcSEcCtD
Modafinil—Dizziness—Mycophenolate mofetil—psoriasis	8.37e-05	0.000278	CcSEcCtD
Modafinil—Skin disorder—Prednisone—psoriasis	8.34e-05	0.000277	CcSEcCtD
Modafinil—Hyperhidrosis—Prednisone—psoriasis	8.3e-05	0.000275	CcSEcCtD
Modafinil—Asthenia—Hydrocortisone—psoriasis	8.28e-05	0.000275	CcSEcCtD
Modafinil—Vomiting—Cyclosporine—psoriasis	8.25e-05	0.000274	CcSEcCtD
Modafinil—Rash—Cyclosporine—psoriasis	8.18e-05	0.000272	CcSEcCtD
Modafinil—Anorexia—Prednisone—psoriasis	8.18e-05	0.000271	CcSEcCtD
Modafinil—Dermatitis—Cyclosporine—psoriasis	8.18e-05	0.000271	CcSEcCtD
Modafinil—Pruritus—Hydrocortisone—psoriasis	8.16e-05	0.000271	CcSEcCtD
Modafinil—Ill-defined disorder—Methotrexate—psoriasis	8.16e-05	0.000271	CcSEcCtD
Modafinil—CYP1A2—Biological oxidations—CYP2S1—psoriasis	8.15e-05	0.00518	CbGpPWpGaD
Modafinil—Headache—Cyclosporine—psoriasis	8.13e-05	0.00027	CcSEcCtD
Modafinil—Anaemia—Methotrexate—psoriasis	8.12e-05	0.000269	CcSEcCtD
Modafinil—Feeling abnormal—Dexamethasone—psoriasis	8.12e-05	0.000269	CcSEcCtD
Modafinil—Feeling abnormal—Betamethasone—psoriasis	8.12e-05	0.000269	CcSEcCtD
Modafinil—Gastrointestinal pain—Betamethasone—psoriasis	8.06e-05	0.000267	CcSEcCtD
Modafinil—Gastrointestinal pain—Dexamethasone—psoriasis	8.06e-05	0.000267	CcSEcCtD
Modafinil—Vomiting—Mycophenolate mofetil—psoriasis	8.05e-05	0.000267	CcSEcCtD
Modafinil—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	8.04e-05	0.00511	CbGpPWpGaD
Modafinil—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	8.03e-05	0.0051	CbGpPWpGaD
Modafinil—Hypersensitivity—Triamcinolone—psoriasis	8e-05	0.000265	CcSEcCtD
Modafinil—Rash—Mycophenolate mofetil—psoriasis	7.98e-05	0.000265	CcSEcCtD
Modafinil—Dermatitis—Mycophenolate mofetil—psoriasis	7.98e-05	0.000265	CcSEcCtD
Modafinil—Headache—Mycophenolate mofetil—psoriasis	7.93e-05	0.000263	CcSEcCtD
Modafinil—Malaise—Methotrexate—psoriasis	7.93e-05	0.000263	CcSEcCtD
Modafinil—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	7.9e-05	0.00502	CbGpPWpGaD
Modafinil—Vertigo—Methotrexate—psoriasis	7.9e-05	0.000262	CcSEcCtD
Modafinil—Diarrhoea—Hydrocortisone—psoriasis	7.89e-05	0.000262	CcSEcCtD
Modafinil—Urticaria—Betamethasone—psoriasis	7.83e-05	0.00026	CcSEcCtD
Modafinil—Urticaria—Dexamethasone—psoriasis	7.83e-05	0.00026	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Prednisone—psoriasis	7.82e-05	0.000259	CcSEcCtD
Modafinil—Dizziness—Prednisolone—psoriasis	7.81e-05	0.000259	CcSEcCtD
Modafinil—Asthenia—Triamcinolone—psoriasis	7.79e-05	0.000259	CcSEcCtD
Modafinil—Body temperature increased—Betamethasone—psoriasis	7.79e-05	0.000258	CcSEcCtD
Modafinil—Abdominal pain—Dexamethasone—psoriasis	7.79e-05	0.000258	CcSEcCtD
Modafinil—Abdominal pain—Betamethasone—psoriasis	7.79e-05	0.000258	CcSEcCtD
Modafinil—Body temperature increased—Dexamethasone—psoriasis	7.79e-05	0.000258	CcSEcCtD
Modafinil—Insomnia—Prednisone—psoriasis	7.76e-05	0.000258	CcSEcCtD
Modafinil—Nausea—Cyclosporine—psoriasis	7.71e-05	0.000256	CcSEcCtD
Modafinil—Paraesthesia—Prednisone—psoriasis	7.71e-05	0.000256	CcSEcCtD
Modafinil—Pruritus—Triamcinolone—psoriasis	7.69e-05	0.000255	CcSEcCtD
Modafinil—Cough—Methotrexate—psoriasis	7.67e-05	0.000254	CcSEcCtD
Modafinil—Dizziness—Hydrocortisone—psoriasis	7.63e-05	0.000253	CcSEcCtD
Modafinil—Convulsion—Methotrexate—psoriasis	7.62e-05	0.000253	CcSEcCtD
Modafinil—SLC6A3—SLC-mediated transmembrane transport—CP—psoriasis	7.56e-05	0.0048	CbGpPWpGaD
Modafinil—Dyspepsia—Prednisone—psoriasis	7.56e-05	0.000251	CcSEcCtD
Modafinil—Nausea—Mycophenolate mofetil—psoriasis	7.52e-05	0.00025	CcSEcCtD
Modafinil—Arthralgia—Methotrexate—psoriasis	7.48e-05	0.000248	CcSEcCtD
Modafinil—Myalgia—Methotrexate—psoriasis	7.48e-05	0.000248	CcSEcCtD
Modafinil—Chest pain—Methotrexate—psoriasis	7.48e-05	0.000248	CcSEcCtD
Modafinil—Decreased appetite—Prednisone—psoriasis	7.46e-05	0.000248	CcSEcCtD
Modafinil—Rash—Prednisolone—psoriasis	7.45e-05	0.000247	CcSEcCtD
Modafinil—Dermatitis—Prednisolone—psoriasis	7.44e-05	0.000247	CcSEcCtD
Modafinil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	7.43e-05	0.000247	CcSEcCtD
Modafinil—Fatigue—Prednisone—psoriasis	7.4e-05	0.000245	CcSEcCtD
Modafinil—Headache—Prednisolone—psoriasis	7.4e-05	0.000245	CcSEcCtD
Modafinil—Discomfort—Methotrexate—psoriasis	7.39e-05	0.000245	CcSEcCtD
Modafinil—Constipation—Prednisone—psoriasis	7.34e-05	0.000243	CcSEcCtD
Modafinil—Vomiting—Hydrocortisone—psoriasis	7.33e-05	0.000243	CcSEcCtD
Modafinil—Rash—Hydrocortisone—psoriasis	7.27e-05	0.000241	CcSEcCtD
Modafinil—Dermatitis—Hydrocortisone—psoriasis	7.27e-05	0.000241	CcSEcCtD
Modafinil—Confusional state—Methotrexate—psoriasis	7.23e-05	0.00024	CcSEcCtD
Modafinil—Headache—Hydrocortisone—psoriasis	7.23e-05	0.00024	CcSEcCtD
Modafinil—Dizziness—Triamcinolone—psoriasis	7.18e-05	0.000238	CcSEcCtD
Modafinil—Anaphylactic shock—Methotrexate—psoriasis	7.17e-05	0.000238	CcSEcCtD
Modafinil—Infection—Methotrexate—psoriasis	7.13e-05	0.000236	CcSEcCtD
Modafinil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.09e-05	0.00451	CbGpPWpGaD
Modafinil—Feeling abnormal—Prednisone—psoriasis	7.07e-05	0.000235	CcSEcCtD
Modafinil—Asthenia—Dexamethasone—psoriasis	7.07e-05	0.000235	CcSEcCtD
Modafinil—Asthenia—Betamethasone—psoriasis	7.07e-05	0.000235	CcSEcCtD
Modafinil—Nervous system disorder—Methotrexate—psoriasis	7.03e-05	0.000233	CcSEcCtD
Modafinil—CYP1A2—Tryptophan metabolism—CAT—psoriasis	7.03e-05	0.00447	CbGpPWpGaD
Modafinil—Gastrointestinal pain—Prednisone—psoriasis	7.02e-05	0.000233	CcSEcCtD
Modafinil—Nausea—Prednisolone—psoriasis	7.02e-05	0.000233	CcSEcCtD
Modafinil—Pruritus—Dexamethasone—psoriasis	6.97e-05	0.000231	CcSEcCtD
Modafinil—Pruritus—Betamethasone—psoriasis	6.97e-05	0.000231	CcSEcCtD
Modafinil—Skin disorder—Methotrexate—psoriasis	6.97e-05	0.000231	CcSEcCtD
Modafinil—Hyperhidrosis—Methotrexate—psoriasis	6.93e-05	0.00023	CcSEcCtD
Modafinil—Vomiting—Triamcinolone—psoriasis	6.91e-05	0.000229	CcSEcCtD
Modafinil—Nausea—Hydrocortisone—psoriasis	6.85e-05	0.000227	CcSEcCtD
Modafinil—Rash—Triamcinolone—psoriasis	6.85e-05	0.000227	CcSEcCtD
Modafinil—Dermatitis—Triamcinolone—psoriasis	6.84e-05	0.000227	CcSEcCtD
Modafinil—Anorexia—Methotrexate—psoriasis	6.84e-05	0.000227	CcSEcCtD
Modafinil—Urticaria—Prednisone—psoriasis	6.82e-05	0.000226	CcSEcCtD
Modafinil—Headache—Triamcinolone—psoriasis	6.8e-05	0.000226	CcSEcCtD
Modafinil—Abdominal pain—Prednisone—psoriasis	6.79e-05	0.000225	CcSEcCtD
Modafinil—Body temperature increased—Prednisone—psoriasis	6.79e-05	0.000225	CcSEcCtD
Modafinil—Diarrhoea—Dexamethasone—psoriasis	6.74e-05	0.000224	CcSEcCtD
Modafinil—Diarrhoea—Betamethasone—psoriasis	6.74e-05	0.000224	CcSEcCtD
Modafinil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.71e-05	0.00426	CbGpPWpGaD
Modafinil—Hypotension—Methotrexate—psoriasis	6.7e-05	0.000222	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Methotrexate—psoriasis	6.54e-05	0.000217	CcSEcCtD
Modafinil—Dizziness—Dexamethasone—psoriasis	6.52e-05	0.000216	CcSEcCtD
Modafinil—Dizziness—Betamethasone—psoriasis	6.52e-05	0.000216	CcSEcCtD
Modafinil—Insomnia—Methotrexate—psoriasis	6.49e-05	0.000215	CcSEcCtD
Modafinil—Nausea—Triamcinolone—psoriasis	6.45e-05	0.000214	CcSEcCtD
Modafinil—Paraesthesia—Methotrexate—psoriasis	6.44e-05	0.000214	CcSEcCtD
Modafinil—Dyspnoea—Methotrexate—psoriasis	6.4e-05	0.000212	CcSEcCtD
Modafinil—Somnolence—Methotrexate—psoriasis	6.38e-05	0.000212	CcSEcCtD
Modafinil—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	6.37e-05	0.00404	CbGpPWpGaD
Modafinil—Hypersensitivity—Prednisone—psoriasis	6.32e-05	0.00021	CcSEcCtD
Modafinil—Dyspepsia—Methotrexate—psoriasis	6.31e-05	0.000209	CcSEcCtD
Modafinil—CYP3A4—Biological oxidations—CYP2S1—psoriasis	6.29e-05	0.004	CbGpPWpGaD
Modafinil—Vomiting—Dexamethasone—psoriasis	6.27e-05	0.000208	CcSEcCtD
Modafinil—Vomiting—Betamethasone—psoriasis	6.27e-05	0.000208	CcSEcCtD
Modafinil—Decreased appetite—Methotrexate—psoriasis	6.24e-05	0.000207	CcSEcCtD
Modafinil—Rash—Dexamethasone—psoriasis	6.21e-05	0.000206	CcSEcCtD
Modafinil—Rash—Betamethasone—psoriasis	6.21e-05	0.000206	CcSEcCtD
Modafinil—Dermatitis—Dexamethasone—psoriasis	6.21e-05	0.000206	CcSEcCtD
Modafinil—Dermatitis—Betamethasone—psoriasis	6.21e-05	0.000206	CcSEcCtD
Modafinil—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	6.21e-05	0.00394	CbGpPWpGaD
Modafinil—Gastrointestinal disorder—Methotrexate—psoriasis	6.19e-05	0.000205	CcSEcCtD
Modafinil—Fatigue—Methotrexate—psoriasis	6.18e-05	0.000205	CcSEcCtD
Modafinil—Headache—Betamethasone—psoriasis	6.17e-05	0.000205	CcSEcCtD
Modafinil—Headache—Dexamethasone—psoriasis	6.17e-05	0.000205	CcSEcCtD
Modafinil—Asthenia—Prednisone—psoriasis	6.16e-05	0.000204	CcSEcCtD
Modafinil—Pain—Methotrexate—psoriasis	6.13e-05	0.000203	CcSEcCtD
Modafinil—ADRA1B—LPA receptor mediated events—CXCL8—psoriasis	6.12e-05	0.00389	CbGpPWpGaD
Modafinil—Pruritus—Prednisone—psoriasis	6.07e-05	0.000201	CcSEcCtD
Modafinil—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.06e-05	0.00385	CbGpPWpGaD
Modafinil—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	6.03e-05	0.00383	CbGpPWpGaD
Modafinil—Feeling abnormal—Methotrexate—psoriasis	5.91e-05	0.000196	CcSEcCtD
Modafinil—Diarrhoea—Prednisone—psoriasis	5.87e-05	0.000195	CcSEcCtD
Modafinil—Gastrointestinal pain—Methotrexate—psoriasis	5.87e-05	0.000195	CcSEcCtD
Modafinil—Nausea—Dexamethasone—psoriasis	5.85e-05	0.000194	CcSEcCtD
Modafinil—Nausea—Betamethasone—psoriasis	5.85e-05	0.000194	CcSEcCtD
Modafinil—Urticaria—Methotrexate—psoriasis	5.7e-05	0.000189	CcSEcCtD
Modafinil—ADRA1B—LPA receptor mediated events—JUN—psoriasis	5.69e-05	0.00361	CbGpPWpGaD
Modafinil—Dizziness—Prednisone—psoriasis	5.68e-05	0.000188	CcSEcCtD
Modafinil—Abdominal pain—Methotrexate—psoriasis	5.67e-05	0.000188	CcSEcCtD
Modafinil—Body temperature increased—Methotrexate—psoriasis	5.67e-05	0.000188	CcSEcCtD
Modafinil—ADRA1B—LPA receptor mediated events—NFKB1—psoriasis	5.48e-05	0.00348	CbGpPWpGaD
Modafinil—Vomiting—Prednisone—psoriasis	5.46e-05	0.000181	CcSEcCtD
Modafinil—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.43e-05	0.00345	CbGpPWpGaD
Modafinil—Rash—Prednisone—psoriasis	5.41e-05	0.00018	CcSEcCtD
Modafinil—Dermatitis—Prednisone—psoriasis	5.41e-05	0.000179	CcSEcCtD
Modafinil—Headache—Prednisone—psoriasis	5.38e-05	0.000178	CcSEcCtD
Modafinil—Hypersensitivity—Methotrexate—psoriasis	5.29e-05	0.000175	CcSEcCtD
Modafinil—ADRA1B—GPCR downstream signaling—HCAR2—psoriasis	5.27e-05	0.00335	CbGpPWpGaD
Modafinil—Asthenia—Methotrexate—psoriasis	5.15e-05	0.000171	CcSEcCtD
Modafinil—Nausea—Prednisone—psoriasis	5.1e-05	0.000169	CcSEcCtD
Modafinil—Pruritus—Methotrexate—psoriasis	5.08e-05	0.000168	CcSEcCtD
Modafinil—Diarrhoea—Methotrexate—psoriasis	4.91e-05	0.000163	CcSEcCtD
Modafinil—ADRA1B—GPCR ligand binding—CCL20—psoriasis	4.85e-05	0.00308	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—HCAR2—psoriasis	4.79e-05	0.00304	CbGpPWpGaD
Modafinil—Dizziness—Methotrexate—psoriasis	4.74e-05	0.000157	CcSEcCtD
Modafinil—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	4.7e-05	0.00299	CbGpPWpGaD
Modafinil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.68e-05	0.00297	CbGpPWpGaD
Modafinil—Vomiting—Methotrexate—psoriasis	4.56e-05	0.000151	CcSEcCtD
Modafinil—Rash—Methotrexate—psoriasis	4.52e-05	0.00015	CcSEcCtD
Modafinil—Dermatitis—Methotrexate—psoriasis	4.52e-05	0.00015	CcSEcCtD
Modafinil—Headache—Methotrexate—psoriasis	4.49e-05	0.000149	CcSEcCtD
Modafinil—Nausea—Methotrexate—psoriasis	4.26e-05	0.000141	CcSEcCtD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	3.91e-05	0.00248	CbGpPWpGaD
Modafinil—SLC6A3—Transmembrane transport of small molecules—CP—psoriasis	3.84e-05	0.00244	CbGpPWpGaD
Modafinil—SLC6A3—Transmembrane transport of small molecules—CARM1—psoriasis	3.66e-05	0.00233	CbGpPWpGaD
Modafinil—ADRA1B—AMPK Signaling—TP53—psoriasis	3.54e-05	0.00225	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.38e-05	0.00214	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.25e-05	0.00206	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	2.95e-05	0.00187	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—HCAR2—psoriasis	2.83e-05	0.0018	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—NDUFA5—psoriasis	2.78e-05	0.00177	CbGpPWpGaD
Modafinil—ADRA1B—GPCR downstream signaling—CCL20—psoriasis	2.74e-05	0.00174	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—NDUFA5—psoriasis	2.72e-05	0.00173	CbGpPWpGaD
Modafinil—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.67e-05	0.00169	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.53e-05	0.00161	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.53e-05	0.00161	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—CCL20—psoriasis	2.49e-05	0.00158	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—TAGAP—psoriasis	2.45e-05	0.00156	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—CYP2S1—psoriasis	2.37e-05	0.0015	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—CYP2S1—psoriasis	2.31e-05	0.00147	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—NDUFA5—psoriasis	2.1e-05	0.00134	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.96e-05	0.00125	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—NDUFA5—psoriasis	1.92e-05	0.00122	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—CYP2S1—psoriasis	1.79e-05	0.00114	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.79e-05	0.00114	CbGpPWpGaD
Modafinil—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.72e-05	0.00109	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—NDUFA5—psoriasis	1.64e-05	0.00104	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—CYP2S1—psoriasis	1.63e-05	0.00104	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.53e-05	0.000971	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CCL20—psoriasis	1.47e-05	0.000933	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—CYP2S1—psoriasis	1.39e-05	0.000885	CbGpPWpGaD
Modafinil—ADRA1B—GPCR ligand binding—CXCL8—psoriasis	1.31e-05	0.000831	CbGpPWpGaD
Modafinil—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.3e-05	0.000828	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—NDUFA5—psoriasis	1.27e-05	0.000804	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—CARM1—psoriasis	1.16e-05	0.000734	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—CARM1—psoriasis	1.13e-05	0.000718	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—CYP2S1—psoriasis	1.08e-05	0.000683	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.38e-06	0.000596	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—CARM1—psoriasis	8.74e-06	0.000555	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.55e-06	0.000543	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.17e-06	0.000519	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—SOCS1—psoriasis	8.09e-06	0.000514	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—CARM1—psoriasis	7.97e-06	0.000506	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—TYK2—psoriasis	7.72e-06	0.00049	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.45e-06	0.000473	CbGpPWpGaD
Modafinil—ADRA1B—GPCR downstream signaling—CXCL8—psoriasis	7.4e-06	0.00047	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.31e-06	0.000464	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—CAT—psoriasis	7.11e-06	0.000452	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—CAT—psoriasis	6.95e-06	0.000441	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—CARM1—psoriasis	6.81e-06	0.000432	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—CXCL8—psoriasis	6.72e-06	0.000427	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.36e-06	0.000404	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—LEP—psoriasis	5.97e-06	0.000379	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—APOE—psoriasis	5.97e-06	0.000379	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—NFKBIA—psoriasis	5.57e-06	0.000353	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—APOE—psoriasis	5.53e-06	0.000351	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—APOE—psoriasis	5.4e-06	0.000343	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—CAT—psoriasis	5.37e-06	0.000341	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—CARM1—psoriasis	5.25e-06	0.000334	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—CAT—psoriasis	4.9e-06	0.000311	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—PPARG—psoriasis	4.81e-06	0.000306	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—PPARG—psoriasis	4.71e-06	0.000299	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—TYK2—psoriasis	4.56e-06	0.000289	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—CAT—psoriasis	4.19e-06	0.000266	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—APOE—psoriasis	4.18e-06	0.000265	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CXCL8—psoriasis	3.97e-06	0.000252	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—APOE—psoriasis	3.81e-06	0.000242	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—IL6—psoriasis	3.77e-06	0.00024	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—JUN—psoriasis	3.69e-06	0.000234	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—PPARG—psoriasis	3.64e-06	0.000231	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—NFKB1—psoriasis	3.55e-06	0.000226	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—PPARG—psoriasis	3.32e-06	0.000211	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—APOE—psoriasis	3.25e-06	0.000207	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—CAT—psoriasis	3.23e-06	0.000205	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—VEGFA—psoriasis	3.22e-06	0.000205	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—STAT3—psoriasis	3.19e-06	0.000203	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—PPARG—psoriasis	2.83e-06	0.00018	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—APOE—psoriasis	2.51e-06	0.000159	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—TP53—psoriasis	2.44e-06	0.000155	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—IL6—psoriasis	2.23e-06	0.000142	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—PPARG—psoriasis	2.19e-06	0.000139	CbGpPWpGaD
